Is The Viral 'Quad-demic' Still Swirling? Know The Good, Bad And Ugly

Updated Feb 7, 2025 | 01:00 AM IST

SummaryFlu, COVID-19, RSV, and norovirus are spreading at high levels in the U.S., causing overlapping symptoms like fever, fatigue, and nausea. Are early testing and vaccination enough to preventing severe infections with overlapping symptoms?
Is The Viral 'Quad-demic' Still Swirling? Know The Good, Bad And Ugly

Image Credit: Health and me

There's been an alarming increase of respiratory and gastrointestinal viruses in the United States lately, causing anxiety about a so-called "quad-demic". According to surveillance reports, influenza, COVID-19, RSV and norovirus are at very high levels everywhere. While the surge aligns with patterns typical for this season, several epidemiologists view simultaneous infections of such proportions to pose risks not only to individual healthcare but public health.

The incidence of the quad-demic should vary with seasonal patterns, vaccination rates, and public health interventions. Each virus alone is relatively easy to manage; however, the effect of all together could lead to overburdening of health care facilities and increase risks for those at higher risk. Continuing surveillance, early testing, and proactive prevention measures will play an important role in the control of these infections going forward.

While the term "quad-demic" sounds daunting, it must be taken into perspective. For years, we have had all these viruses together, and we have the capabilities to mitigate some of the risk. Vaccination, proper hygiene and using common sense helps individuals get through the season unscathed. Is the quad-demic a permanent fixture or just another seasonal wave? Let's break this down.

What is the Quad-demic?

Typically, flu, COVID-19, and RSV have been the primary culprits behind seasonal respiratory infections. However, norovirus, a highly contagious stomach bug, has emerged as a fourth significant player, inducing fears of a more severe and widespread viral outbreak. According to the Centers for Disease Control and Prevention (CDC), the U.S. recorded nearly 500 norovirus outbreaks between August and December 2023, a substantial rise from the previous year’s numbers.

While the term "quad-demic" may sound ominous, the seriousness and consequences of such infections should be weighed in light of the U.S. healthcare system's experience with managing viral surges since the start of the COVID-19 pandemic.

1. Influenza (Flu)

Flu continues to be one of the most common and alarming seasonal illnesses. In the period spanning from 2023 to 2024, there were approximately 40 million cases of flu, and thousands of hospitalizations along with reported 47 deaths have been reported this season. Flu symptoms include fever, chills, cough, sore throat, muscle pain, and fatigue, with most recovering within a week or two but risky factors for severe illness effects occur in young children, elderly, and people with chronic conditions.

2. Covid-19

Despite its reduction from the first pandemic peak, COVID-19 is still rampant. The CDC estimates that alone between October and December 2023, there were between 2.7 and 5 million cases in the U.S. Hospitalization has increased by cities such as Los Angeles, Chicago, and New York. Symptoms are closely similar to the flu, fever, cough, and fatigue but uniquely presents in some cases as loss of taste and smell.

3. RSV

RSV is the most common cause of lower respiratory infections in infants, older adults, and immunocompromised individuals. While RSV peaked late in 2023 and early 2024, it continues to be a threat because it can lead to bronchiolitis and pneumonia. It is very similar to the common cold, presenting with symptoms such as congestion, runny nose, coughing, and fever, which can make it difficult to differentiate from flu or COVID-19 without testing.

4. Norovirus

Norovirus, also called the "stomach flu," is a highly contagious infection of the gastrointestinal tract, not a respiratory virus. It transmits quickly from contaminated food and water and contact with contaminated surfaces, causing such symptoms as diarrhea, vomiting, nausea, and stomach pain. Cases have shot up, the CDC said Monday, with reports of outbreaks surging compared with last year.

Is There a Challenge In Diagnosis Due to Overlapping Symptoms?

The greatest challenge during the quad-demic is how the four viruses are alike and thus make identification very hard with no testing applied. Most cases present symptoms common to all viruses: fever, tiredness, body pains, and respiratory, which includes coughing and congestions for influenza, COVID-19, and RSV; the other would be norovirus symptoms as nausea and vomiting can appear even in extreme influenza and COVID-19. This overlap increases the risk of misdiagnosis and delayed treatment, hence the need for early testing and proper medical guidance.

Also Read: Is US Preparing For A Quad- demic 2025?

Effective Prevention Strategies That Work

The best defense against these viruses is a combination of vaccines, hygiene, and lifestyle precautions. While lifestyle modifications are highlighted as part of the constant need to eat healthy, ensure daily movement and drinking adequate amount of fluids. There is a sure short two preventive strategies that are effective:

Vaccination

  • Flu vaccine: Annual flu shots reduce the severity of infection, allergic flare ups and hospitalizations.
  • COVID-19 vaccine: Though COVID-19 cases have declined, vaccination remains critical in preventing severe outcomes.
  • RSV vaccine: Available for those aged 60 years and older, especially those with underlying conditions.
  • Norovirus vaccine: No vaccine is yet available, but mRNA vaccine research is in progress.

Hygiene and Sanitation

  • Washing hands frequently with soap and water for at least 20 seconds, especially after public exposure.
  • Disinfect frequently touched surfaces regularly, use sanitiser when outside.
  • Avoid close contact with infected people and wear masks.

Do You Need To Wear A Mask All The Time?

While debates on masked wear continue on, experts on mask-wear affirm that this does not only have a historical precedent but works towards reducing airborne viruses spreading within the environments. Hospitals, though, ensure masking in key sections of themselves. Publicized mask-wear remains a discretion, though massing indoors still goes a longer way in cases like peak flu seasons.

If you notice the symptoms of these viruses, then it's best to be confined at home and avoid having face-to-face interaction with others and seek immediate attention from your physician if your condition worsens. Quarantining for some days can decrease the spread of infection.

As we move into the first half of 2025 and beyond, staying informed and proactive is the best strategy for maintaining health and avoiding unnecessary panic. The key takeaway? Stay vigilant, but don’t be alarmed—these viruses are here, but so are the means to fight them.

End of Article

US FDA Approves Merck’s Once-daily Combination Pill For Treating Adults With HIV

Updated May 2, 2026 | 12:00 PM IST

SummaryAccording to the latest data from UNAIDS, 40.8 million people globally were living with HIV in 2024. Of these,­ 39.4 million were adults (15 years or older) and 1.4 million were children (0–14 years).
US FDA Approves Merck’s Once-daily Combination Pill For Treating Adults With HIV

Credit: iStock/Merck

The US Food and Drug Administration (FDA) has approved Merck's Idvynso (doravirine/islatravir), a new, once-daily pill for the treatment of HIV-1 infection in adults.

The two-drug single tablet replaces the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA <50 copies per mL).

The single tablet contains 100 mg doravirine and 0.25 mg islatravir. The FDA has approved it for adults on a stable antiretroviral regimen with no history of virologic treatment failure and no known substitutions associated with resistance to doravirine.

“IDVYNSO combines islatravir, a next-generation NRTI with multiple mechanisms of action, including translocation inhibition, with doravirine, an NNRTI with an established efficacy and safety profile,” said Dr. Eliav Barr, senior vice president and chief medical officer, Merck Research Laboratories, in a statement.

How Was The Pill Approved?

The approval is based on data from two randomized, active-controlled, noninferiority trials. In the double-blind Trial 052, participants were randomly assigned to stay on Glilead's Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide; 171 individuals) or switch to Idvynso (342 individuals).

Results showed that 1 per cent of participants in both groups had a viral load of ≥50 copies/mL at 48 weeks.

In the open-label Trial 051, participants were randomly assigned to stay on their oral antiretroviral therapy (ART) regimen (185 individuals) or switch to Idvynso (366 individuals).

Results showed that 1 per cent of participants who were switched to Idvynso had a viral load of ≥50 copies/mL at week 48 versus 5 per cent who continued on ART.

"As the only two-drug, non-integrase strand transfer inhibitor, tenofovir-free regimen, Idvynso expands therapeutic diversity beyond the currently available oral treatment options," Barr said.

"As the health needs of adults living with HIV change over time, Idvynso gives clinicians a new choice for HIV treatment."

What Is IDVYNSO? How Does It Work?

IDVYNSO is a fixed-dose combination of two medicines, doravirine with islatravir.

Doravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that inhibits HIV-1 replication by non-competitive inhibition of HIV-1 reverse transcriptase.

Islatravir is a potent, next-generation nucleoside analog reverse transcriptase inhibitor (NRTI) that blocks HIV-1 replication by multiple mechanisms, including:

  • inhibition of reverse transcriptase translocation, resulting in immediate chain termination,
  • induction of structural changes in the viral DNA (delayed chain termination).
IDVYNSO is a complete regimen; co-administration with other antiretroviral medications for treatment of HIV-1 infection is not recommended.

Global Burden Of HIV

According to the latest data from UNAIDS, 40.8 million people globally were living with HIV in 2024. Of these, 39.4 million were adults (15 years or older) and 1.4 million were children (0–14 years).

While 1.3 million people became newly infected with HIV in 2024, 630,000 died from AIDS-related illnesses.

About 87 per cent of all people living with HIV knew their HIV status, and 5.3 million people did not know that they were living with HIV.

End of Article

CDC Warns Over Potential Surge In Measles Cases: Will The US Lose Its Elimination Status?

Updated May 2, 2026 | 10:12 AM IST

SummarySo far, there have been 24 new measles outbreaks reported in 2026, and 93 per cent of confirmed cases (1,688 of 1,814) are outbreak-associated (415 from outbreaks starting in 2026 and 1,273 from outbreaks that started in 2025).
CDC Warns Over Potential Surge In Measles Cases: Will The US Lose Its Elimination Status?

Credit: AI generated image

The US eliminated measles in 2000, but since 2025, the highly infectious disease has spread to 45 states. As of early May 2026, the US has recorded 1,814 confirmed measles cases this year across 36 states. This follows a record-high 2,288 cases in 2025.

Now, the US Centers for Disease Control (CDC) has warned about additional measles cases ahead of the travel season.

The CDC urged public health agencies across the US to be prepared for more measles cases in the coming months.

"With continued measles transmission in areas across North America and expected increases in international and domestic travel and large events during spring and summer, additional measles cases are anticipated in the coming months," the agency said.

Travel Guidance By CDC

The guidance advised public health agencies to document and report details of each case of measles, including close contacts and locations visited while a person was infectious.

Active surveillance should be conducted to identify any additional suspected cases and quickly transport specimens for laboratory confirmation, the guidance said.

The agency also encouraged outreach to under-vaccinated communities and suggested using state-based syndromic surveillance systems to detect changes in health care–seeking behavior for fever and rash illnesses or signs of vitamin A toxicity.

Measles is a highly contagious virus that spreads through direct contact or through the air when an infected person coughs or sneezes. It is a vaccine-preventable disease that can cause devastating complications, including blindness, pneumonia, encephalitis, and long-term immune dysfunction.

Is The US At Risk Of Losing Measles Elimination Status?

Also read: Robert F. Kennedy Jr. Denies Link To Measles Outbreak At Senate Hearing

So far, there have been 24 new outbreaks reported in 2026, and 93 per cent of confirmed cases (1,688 of 1,814) are outbreak-associated (415 from outbreaks starting in 2026 and 1,273 from outbreaks that started in 2025).

In 2025, 48 outbreaks were reported, and 90 per cent of confirmed cases (2,065 of 2,288) were outbreak-associated.

According to researchers at Boston Children's Hospital, the US has missed four of the seven criteria for measles elimination status, which could put the country off track. More are at risk, they said.

In a Correspondence published in The Lancet, the researchers explained the missed indicators of measles elimination status in the US.

  • Low number of cases with a cutoff of less than one case per 10 million people. As of early 2026, the US had about 93 cases per 10 million people, exceeding this limit.

  • Most of the measles cases should come from abroad rather than from internal spread. Since the start of 2025, only 6–7 per cent of the measles cases have come from abroad, meaning most cases derive from within the US.

  • A limited number of outbreaks (a cutoff of approximately four) with no more than about six cases each. Last year in the US, 48 outbreaks resulted in more than 2,000 cases. And in early 2026, at least 19 outbreaks have already resulted in more than 1,600 cases.

  • A level of transmission less than one, meaning one infected person only spreads measles to fewer than one other person on average. The US exceeded this rate more than 75 per cent of the time since early 2025.

Indicators At Risk

Read More: India Concerned Over Measles Outbreak, Action Underway: Dr N K Arora| Exclusive

  • The country achieves four weeks with all infections deriving from outside the US. Since the first infection in January 2025, the US hasn't gone four weeks without infections, with 90 per cent of cases acquired here.

  • Herd immunity through vaccination. An estimated 95 per cent of people need to receive two doses of the measles vaccine to achieve herd immunity, typically given as part of the MMR (measles, mumps, and rubella) vaccine. However, the US average vaccination rate of kindergartners in the 2024–2025 school year was 92 per cent, meaning this indicator is at high risk.

  • Measles cases don't share a common viral strain. From ongoing genetic analyses, preliminary data show that the majority of cases share the same viral strain and are likely part of the same transmission chain.

The researchers believe these findings make a strong case for vaccinating children to protect them from a young age.

"Viral infections aren't all benign, and a measles infection, even when cleared, can result in lifelong problems," said Maimuna Majumder, from Boston Children's.

"Babies less than a year old are among those at greatest risk for severe complications, and the full impact on children exposed during the current outbreak may only show up years later," Majumder added.

End of Article

Meet REDMOD: An AI Model That Diagnoses Pancreatic Cancer Long Before Signs Appear

Updated May 1, 2026 | 10:00 PM IST

SummaryPancreatic cancer has a high mortality rate because it is usually diagnosed at an advanced stage.
Pancreatic cancer

The sooner REDMOD is implemented, the better for pancreatic cancer patients.

Pancreatic cancer is one of the most painful forms of tumour and is also likely to become the second-leading cause of cancer-related deaths in the US by 2030. This could be because 85 per cent of cancer cases in the US are not diagnosed until the disease has spread. Pancreatic cancer is a disease that is usually diagnosed at an advanced stage because there are no prominent early signs. However, a newly developed AI model from the Mayo Clinic and the University of Texas MD Anderson Cancer Center could change that—a new CT scan-based system can help with the timely diagnosis of pancreatic cancer.

Can AI help with pancreatic cancer diagnosis?

REDMOD (radiomics-based early detection model) was tested on CT scans of patients who were later diagnosed with pancreatic cancer. Researchers found that in nearly three out of four cases, REDMOD successfully identified the most common form of pancreatic cancer 16 months before diagnosis. It nearly doubled the detection rate of specialists reviewing scans without AI assistance. In some cases, REDMOD recognised suspicious tissue patterns more than two years before diagnosis. Researchers said that the AI system can detect cancer up to three years in advance.

How does AI work for pancreatic cancer diagnosis?

Experts found that the greatest barrier to saving lives from pancreatic cancer was the inability to detect the tumour when it was still curable. AI can identify cancer signs from a normal-looking pancreas, and it can do so reliably across clinical settings. Researchers used 969 CT scans of the pancreas as training data for REDMOD to help it detect early-stage cancer signs.

Instead of looking for a prominent tumour, the model analysed radiomic patterns that disrupt tissue structure and texture—changes that are too subtle for the human eye to detect. Many cancers begin when normal cells acquire DNA mutations, which affect how cells divide and grow. However, it can take years before these changes develop into a tumour that produces symptoms or becomes clearly visible on a scan.

How accurate was REDMOD at diagnosing pancreatic cancer?

REDMOD was tested on a varied set of CT scans after training — 63 from patients who later developed cancer but were scanned before diagnosis, and 430 from healthy individuals. Out of the 63 cases, REDMOD flagged 46 as suspicious, resulting in a 73 per cent success rate. All these scans had previously been given the all-clear by radiologists who evaluated them at the same time as REDMOD.

Out of the 430 healthy individuals, 81 were identified as suspicious cases by REDMOD. This means that if AI were deployed in a real-world scenario, some individuals might be recommended for additional tests before receiving a final all-clear. A similar performance was observed in two other datasets from different hospitals using different equipment. For patients who had multiple scans available, AI produced consistent results, even when the scans were taken months apart.

Are there any drawbacks of REDMOD?

The sooner REDMOD is implemented in clinical practice, the earlier it can detect pancreatic cancer. It could identify tumours at a stage when treatment is still possible. This could significantly improve survival rates and reduce cancer-related mortality. However, researchers now aim to test the effectiveness of AI in larger and more diverse populations.

The research has been published in the Gut.

End of Article